AZ 628

製品コードS2746

AZ 628化学構造

分子量(MW):451.52

AZ628は一種の新たなpan-Raf阻害剤で、無細胞試験でBRAF、BRAFV600Eとc-Raf-1に作用する時のIC50値が105 nM、34 nMと29 nMにそれぞれ分かれることですが、VEGFR2、DDR2、Lyn、Flt1とFMS等も抑制します。

サイズ 価格 在庫  
USD 340 あり
USD 189 あり
USD 592 あり

カスタマーフィードバック(2)

  • A375 cells were infected with the indicated shRNAs/ORFs. In parallel to the above, cells were also treated with 0.2 uM AZ628 for 16 h, cell lysates were analyzed by Western blotting for the indicated proteins.

    Cancer Discov 2013 3(3), 350-62. AZ 628 purchased from Selleck.

    Enzymatic activity of RIP3 from Abcam, the concentration-effect relationship of RIP3 inhibition by the tested protein kinase inhibitors and the mode of action of RIP3 inhibition by dabrafenib. The RIP3 inhibition rates of AZ628 at different concentrations were measured by the luminescent RIP3 assay. The data (mean ?SD from 3 independent experiments) were presented as the Lineweaver-Burk plots using Graphpad Prism 5.

    Cell Death Dis 2014 5, e1278. AZ 628 purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 AZ628は一種の新たなpan-Raf阻害剤で、無細胞試験でBRAF、BRAFV600Eとc-Raf-1に作用する時のIC50値が105 nM、34 nMと29 nMにそれぞれ分かれることですが、VEGFR2、DDR2、Lyn、Flt1とFMS等も抑制します。
ターゲット
C-Raf-1 [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
29 nM 34 nM 105 nM
体外試験

AZ628 prevents activation of number of tyrosine protein kinases including VEGFR2, DDR2, Lyn, Flt1, FMS and others. AZ628 suppresses anchorage-dependent and -independent growth, gives rise to cell cycle arrest, and induces apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation. The profile of AZ628 cross-reactivity suggests that similar to sorafenib, AZ628 may be antiangiogenic based on prevention of VEGFR2. [1] AZ628-resistant clones are approximately 100-fold more resistant to AZ628 than the parental cell line, exhibiting IC50 of approximately 10 μM, compared with 0.1 μM for the parental cell line. Effective suppression of p-ERK1/2 levels is observed in the M14 parental cell line following treatment with increasing concentrations of AZ628. AZ628-resistant clones express elevated CRAF. Elevated CRAF expression is a potential mechanism of acquired resistance to continuous AZ628 exposure, resulting in sustained activation of ERK1/2. p-ERK1/2 activity is not significantly inhibited by exposure to AZ628 in one of these three AZ628-insensitive cell lines (Wm1552C). Unlike in the AZ628-resistant M14 cells in which AZ628 fails to suppress the activation of ERK, AZ628 treatment efficiently attenuates ERK activation in the NRAS mutant melanoma cells.[2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ACN cell NGm0eXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3r6TmlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNFEhdk1? NVq1PJZ4W0GQR1XS
SH-4 cell NFTG[XZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLBTY5pcWKrdHnvckBw\iCqdX3hckBUUC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wNUBvVQ>? MlS0V2FPT0WU
LB2518-MEL cell NHnCfGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIHnUnBKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke2JI5O MVzTRW5ITVJ?
A101D cell MkXzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2T4W2lvcGmkaYTpc44hd2ZiaIXtZY4hSTFyMVSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlgzKG6P MnPFV2FPT0WU
HT-144 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4i0WmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok43OSCwTR?= MUnTRW5ITVJ?
SIG-M5 cell MljQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVzJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOFUhdk1? MkO5V2FPT0WU
DU-4475 cell Mn3aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIi0TZhKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{MzDuUS=> NGnv[HNUSU6JRWK=
A375 cells MYjGeY5kfGmxbjDhd5NigQ>? MUK3OUBucW6| NEnvfGtKdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62LX3l[IlifGWmIFXST{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3OUBucW6|LDDJR|UxRTBwMEG1JO69VQ>? NVjLfGNEOjN|OUi0OVM>
OCI-AML2 cell MnHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkT6TY5pcWKrdHnvckBw\iCqdX3hckBQS0lvQV3MNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF5zszN MXjTRW5ITVJ?
COLO-829 cell NIrKWZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1izb2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24Nlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPS54NTDuUS=> MX;TRW5ITVJ?
PSN1 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYKyT3VVUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlcvOzdibl2= M2S3NHNCVkeHUh?=
UACC-257 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHjBR5JKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjdwNEmgcm0> MnzPV2FPT0WU
RKO cell NG\HbmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN5Lk[3JI5O M{C0RnNCVkeHUh?=
MMAC-SF cell NXf6UYhQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJG1OSUNvU1[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20NE4xPyCwTR?= NYrWRplSW0GQR1XS
Calu-6 cell NIHlOpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojqTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21NU41PyCwTR?= MknkV2FPT0WU
LS-513 cell MmnKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjEenVKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVc1NjF3IH7N NYPy[4pyW0GQR1XS
NOS-1 cell Mn;tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mo\hTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmyMlY2KG6P NEfTV2JUSU6JRWK=
SW872 cell M3L5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OU[uOFghdk1? M{OxbnNCVkeHUh?=
KMOE-2 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzETY5pcWKrdHnvckBw\iCqdX3hckBMVU:HLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVUvQDhibl2= NWHRVmd6W0GQR1XS
MZ7-mel cell MmrzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NInWN|dKdmirYnn0bY9vKG:oIHj1cYFvKE2cNz3t[Ywh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTdwMkegcm0> MmXEV2FPT0WU
CGTH-W-1 cell NXLsUYJqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml3tTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOS5|IH7N NH\3fWhUSU6JRWK=
CP66-MEL cell NIfXXnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmX1TY5pcWKrdHnvckBw\iCqdX3hckBEWDZ4LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{OS55NjDuUS=> NGXCSnNUSU6JRWK=
K5 cell MmnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LZbWlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zM{SuNkBvVQ>? MWPTRW5ITVJ?
HL-60 cell NFPPeFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUnJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUW0MlQyKG6P MUnTRW5ITVJ?
ONS-76 cell NXO3W5pRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfNO|NDUW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPjZwNkKgcm0> MoPLV2FPT0WU
NB69 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOUGuN|Ehdk1? NHy4T2xUSU6JRWK=
LAMA-84 cell M1nWO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzMTY5pcWKrdHnvckBw\iCqdX3hckBNSU2DLUi0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkzNjR{IH7N NEjWTpBUSU6JRWK=
EM-2 cell  NGrSUY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOUWuPVEhdk1? NVi0ZVdnW0GQR1XS
IST-MEL1 cell NVfzVWVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3PPNmlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLV3FUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zODRwMUOgcm0> M2nhTHNCVkeHUh?=
HCC2998 cell M33EUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzOTh5IN88US=> M4nmOnNCVkeHUh?=
GDM-1 cell NYXveVhET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2DHTGlvcGmkaYTpc44hd2ZiaIXtZY4hT0SPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzQTR5IN88US=> NYjwTGtDW0GQR1XS
MZ1-PC cell NEf5N|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlc6QTlizszN Mm\SV2FPT0WU
BB49-HNC cell NHjBV2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;jdow6UW6qaXLpeIlwdiCxZjDoeY1idiCEQkS5MWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{WxPEDPxE1? NWDweFFPW0GQR1XS
D-392MG cell M3WxT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUOwSJJrUW6qaXLpeIlwdiCxZjDoeY1idiCGLUO5Nm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NU[wO{DPxE1? MojEV2FPT0WU
697 cell NYHROWFTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLLO|dHUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOlMvQDhizszN M{fad3NCVkeHUh?=
ML-2 cell NFLz[FFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M17UZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO2PE45PiCwTR?= NH61W4hUSU6JRWK=
MEG-01 cell NX62b3A2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M170[GlvcGmkaYTpc44hd2ZiaIXtZY4hVUWJLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PzZizszN NGnVXohUSU6JRWK=
SK-MEL-1 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnHjTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzh|NkKg{txO NWfGdGV2W0GQR1XS
KS-1 cell M1HmT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYPQWIQyUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTN|NzFOwG0> NXj2b|FqW0GQR1XS
NB14 cell M2fDdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYXJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS5N|MyKM7:TR?= MXLTRW5ITVJ?
NCI-H747 cell MlHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnyWWVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53ME[zO{DPxE1? M4CzbXNCVkeHUh?=
K-562 cell NUPvNmtiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGXCb4tKdmirYnn0bY9vKG:oIHj1cYFvKEtvNU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZ7NTFOwG0> MlfYV2FPT0WU
NCI-H1648 cell MljOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NITaWYVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNkeyOlYh|ryP M1ewOXNCVkeHUh?=
LAN-6 cell M2CyWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NULEOFBLUW6qaXLpeIlwdiCxZjDoeY1idiCOQV6tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjh{M{[g{txO MUnTRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: M14 expressing the V600E BRAF mutation
  • 濃度: 0.01-10 μM
  • 反応時間: Overnight
  • 実験の流れ: Approximately 0.5-2.5 × 105 M14 cells are seeded in 12 or 24 - well plates, respectively, in medium supplemented with 5% FBS. After overnight incubation, the cells are treated with various concentrations of AZ628. Fresh medium and drug is replaced every 2 days until the untreated control wells reached confluence. At this time-point, the media is removed and the cells are fixed in 4% formaldehyde in PBS for 20 minutes at room temperature. Cells are then washed twice with PBS and stained with a 1:5000 solution of the fluorescent nucleic acid stain Syto60. Quantitation of fluorescent signal intensity is carried out at 700 nm, using an Odyssey Infrared Imager. Each experiment is performed in quadruplicate and the results shown represent the average of the four values compared to untreated wells. Error bars represent standard deviation of the 4 values from the mean. High-throughput cell growth/viability assays are performed.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 90 mg/mL (199.32 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 451.52
化学式

C27H25N5O2

CAS No. 878739-06-1
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Raf信号経路図

Raf Inhibitors with Unique Features

相関Raf製品

Tags: AZ 628を買う | AZ 628 ic50 | AZ 628供給者 | AZ 628を購入する | AZ 628費用 | AZ 628生産者 | オーダーAZ 628 | AZ 628化学構造 | AZ 628分子量 | AZ 628代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID